On November 14, MSD announced that Xinruilai®, the world's first and currently only activin signaling inhibitor targeting the potential pathophysiological mechanism of pulmonary hypertension, and Villiary®, the world's first and currently only hypoxia-inducing factor 2α inhibitor, were officially included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”.

Zhitongcaijing · 2d ago
On November 14, MSD announced that Xinruilai®, the world's first and currently only activin signaling inhibitor targeting the potential pathophysiological mechanism of pulmonary hypertension, and Villiary®, the world's first and currently only hypoxia-inducing factor 2α inhibitor, were officially included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”.